
Atea Pharmaceuticals, Inc. (AVIR) Stock Ticker
AVIR right now
Market factors today
Unlock the full AVIR picture
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
AVIR stock facts
| Ticker symbol | AVIR |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $413.7M |
| CEO | Jean-Pierre Sommadossi |
| Employees | 55 |
| Headquarters | Boston, MA, US |
| IPO date | 2020-10-30 |
| Website | www.ateapharma.com |
What you can see for AVIR on Tickr
Live AVIR price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the AVIR report.
Rankings
FAQ
What is the ticker symbol for Atea Pharmaceuticals, Inc.?
The ticker symbol for Atea Pharmaceuticals, Inc. is AVIR, listed on the NASDAQ.
What is AVIR?
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company…